Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this proposed pilot study is to examine the use of varenicline in people with
schizophrenia to specifically assess tolerability and efficacy for smoking cessation.
Specifically, The primary objective of this pilot study is to determine if taking of
varenicline along with an individual smoking cessation supportive program is a safe and
effective treatment of nicotine addiction in schizophrenic patients. We hypothesize that the
varenicline treated patients will achieve higher rates of smoking cessation than those who
receive placebo and individual support.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore